Penn Medicine and Children’s Hospital of Philadelphia remain at the forefront of cell and gene therapy, solidifying Philadelphia’s status as “Cellicon Valley.” The University of Pennsylvania continues to lead in CAR-T cell research, reflecting its ongoing commitment to innovation in this field, particularly through the pioneering work of the Center for Cellular Immunotherapies.

While CAR T-cell therapy has already revolutionized cancer treatment, the field continues to evolve rapidly. This activity provides a unique opportunity to interact with world-renowned experts in CAR T-cell therapy for cancer, hematologic disorders and autoimmune diseases.

Clinicians will discover cutting-edge strategies to optimize patient care and overcome challenges in the field. Researchers will delve into the scientific and technical breakthroughs shaping the future of this revolutionary treatment. Business leaders will gain a comprehensive understanding of the CAR T-cell therapy landscape with a focus on commercial partnering, product development and entrepreneurship.